Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Respir Med. 2013 Feb;7(1):13-7. doi: 10.1586/ers.12.84.

Mepolizumab for severe eosinophilic asthma.

Author information

1
Leukocyte Biology Section, National Heart and Lung Institute, Imperial College London, UK. d.s.robinson@imperial.ac.uk

Abstract

In this large (616 patients), double-blind, placebo-controlled, dose-ranging study of mepolizumab (a monoclonal antibody that blocks IL-5 binding to its receptor), patients were given placebo, 75-, 250- or 750-mg mepolizumab by intravenous infusion every 4 weeks for 1 year. Exacerbation rates at all doses were 50% less than those in the placebo group. There were no changes in any other asthma measures (symptoms, quality of life or lung function). This may be a useful advance for a subgroup of severe asthma with frequent exacerbations and persistent eosinophilia, which may be about half of severe asthmatics. More information on patient selection and cost-benefit will be required.

PMID:
23362812
DOI:
10.1586/ers.12.84
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center